Nordicus Partners Takes Major Steps with Orocidin
Nordicus Partners Corporation (OTCQB: NORD) has made exciting progress that aims to change the landscape of dental health. Through its subsidiary, Orocidin A/S, the company is set to kick off a critical toxicity program for its innovative product, Orocidin (QR-01). This initiative is slated to begin soon, with expectations to wrap up by the third quarter of 2025, leading towards an efficacy study by the year’s end. These developments indicate a promising forward momentum in treating periodontitis.
Breaking Ground with Orocidin (QR-01)
Orocidin (QR-01) is not just another treatment; it represents a breakthrough innovation geared towards addressing the multifaceted challenges posed by periodontitis. This condition is not just about sore gums; it's a chronic inflammatory disease that can lead to tooth loss if not effectively managed. Orocidin aims to tackle this condition head-on by focusing on three notable areas: reducing inflammation, eliminating bacterial threats, and stimulating bone regeneration where it’s needed the most. Protecting its proprietary technology is a priority for Nordicus, which is why patent applications have already been filed.
Leadership’s Vision for Dental Health
Allan Wehnert, the Founder and CEO of Orocidin, expressed his enthusiasm about reaching this pivotal stage of development. "We are thrilled that Orocidin has progressed to this vital phase. This brings us closer to showcasing its effectiveness and ultimately fulfilling a significant unmet need in dental health,” he said. Every step taken is a testament to Nordicus’ unwavering commitment to advancing innovative solutions that hold the potential to enhance lives and provide value to stakeholders.
Contacting Nordicus Partners
For those curious about this frontier in dental health and seeking more information, Nordicus encourages inquiries and is open to discussions. Anyone interested in learning more about Orocidin or the company's plans can reach out to the following contacts:
Mr. Henrik Rouf
Chief Executive Officer
Phone: +1 310 666 0750
Email: hr@nordicuspartners.com
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Email: Jonathan.Paterson@Harbor-Access.com
Phone: +1 475 477 9401
About Nordicus Partners Corporation
Nordicus Partners Corporation is a unique force in the U.S. market, serving as the sole publicly traded business accelerator and holding entity for Nordic life sciences companies. With decades of combined expertise in both domestic and global corporate arenas, Nordicus excels at corporate finance, offering extensive support in various financial activities including business development, growth strategies, and partnership building. The company recently made headlines when it acquired both Orocidin A/S and Bio-Convert ApS, highlighting its commitment to fostering advancements in solutions for dental health, among other areas. For further insights, you can explore more about Nordicus at www.nordicuspartners.com and connect with us on platforms like LinkedIn, X, Threads, and BlueSky.
Frequently Asked Questions
What is Orocidin (QR-01)?
Orocidin (QR-01) is a proprietary product developed by Nordicus aimed at treating periodontitis by reducing inflammation, eradicating bacteria, and promoting bone regeneration.
When will the toxicity program for Orocidin begin?
The toxicity program for Orocidin is set to commence soon and is expected to conclude by the third quarter of 2025.
What are the expected outcomes of the toxicity program?
The primary outcome of the toxicity program is to ensure the safety of Orocidin before moving forward with pilot efficacy studies later in 2025.
Who leads Nordicus Partners Corporation?
The company is led by CEO Allan Wehnert, who is dedicated to advancing innovative solutions in the life sciences sector.
How can I contact Nordicus Partners for more information?
Interested parties can reach out via email at hr@nordicuspartners.com or contact Jonathan Paterson for investor relations by email at Jonathan.Paterson@Harbor-Access.com.
